Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Dropped head syndrome: report of three cases during treatment with a MEK inhibitor.

Chen X, Schwartz GK, DeAngelis LM, Kaley T, Carvajal RD.

Neurology. 2012 Oct 30;79(18):1929-31. doi: 10.1212/WNL.0b013e318271f87e. Epub 2012 Oct 17. No abstract available.

2.

The coming of age of MEK.

McArthur GA.

Lancet Oncol. 2012 Aug;13(8):744-5. doi: 10.1016/S1470-2045(12)70317-0. Epub 2012 Jul 16. No abstract available.

PMID:
22805290
3.

Trametinib for patients with advanced melanoma.

Masuda S, Izpisua Belmonte JC.

Lancet Oncol. 2012 Oct;13(10):e409; author reply e409-10. doi: 10.1016/S1470-2045(12)70419-9. No abstract available.

PMID:
23026823
4.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG.

J Clin Oncol. 2008 May 1;26(13):2139-46. doi: 10.1200/JCO.2007.14.4956. Epub 2008 Apr 7.

5.

Promises from trametinib in RAF active tumors.

Sausville EA.

N Engl J Med. 2012 Jul 12;367(2):171-2. doi: 10.1056/NEJMe1205654. Epub 2012 Jun 4. No abstract available.

PMID:
22663012
6.

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK.

PLoS One. 2012;7(7):e40439. doi: 10.1371/journal.pone.0040439. Epub 2012 Jul 10.

7.

MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.

Facciorusso A, Licinio R, Carr BI, Di Leo A, Barone M.

Expert Rev Gastroenterol Hepatol. 2015 Jul;9(7):993-1003. doi: 10.1586/17474124.2015.1040763. Epub 2015 Apr 27. Review.

PMID:
25915713
8.

Improved survival with MEK inhibition in BRAF-mutated melanoma.

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group.

N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4.

9.

MEK1/2 inhibition delays progression of uveal melanoma.

Gilbert JA.

Lancet Oncol. 2014 Aug;15(9):e366. No abstract available.

PMID:
25225689
10.

Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.

Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, Bastian BC.

Oncogene. 2014 Sep 25;33(39):4724-34. doi: 10.1038/onc.2013.418. Epub 2013 Oct 21.

11.

Long-Term Evaluation of MEK Inhibitor Retinal Toxicity With Multimodal Imaging.

Sheyman AT, Scarinci F, Fawzi AA, Gill MK.

Ophthalmic Surg Lasers Imaging Retina. 2016 Jan;47(1):76-7. doi: 10.3928/23258160-20151214-12.

PMID:
26731214
12.

Selumetinib shows promise in metastatic uveal melanoma.

[No authors listed]

Cancer Discov. 2013 Jul;3(7):OF8. doi: 10.1158/2159-8290.CD-NB2013-086. Epub 2013 Jun 6.

13.

A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).

Boers-Sonderen MJ, Desar IM, Blokx W, Timmer-Bonte JN, van Herpen CM.

Anticancer Drugs. 2012 Aug;23(7):761-4. doi: 10.1097/CAD.0b013e328350737d.

PMID:
22293660
14.

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Holt SV, LogiƩ A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD.

Br J Cancer. 2012 Feb 28;106(5):858-66. doi: 10.1038/bjc.2012.8. Epub 2012 Feb 16.

15.

MEK1/2 inhibitors in the treatment of gynecologic malignancies.

Miller CR, Oliver KE, Farley JH.

Gynecol Oncol. 2014 Apr;133(1):128-37. doi: 10.1016/j.ygyno.2014.01.008. Epub 2014 Jan 14. Review.

PMID:
24434059
16.

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.

Yoon YK, Kim HP, Han SW, Hur HS, Oh DY, Im SA, Bang YJ, Kim TY.

Mol Cancer Ther. 2009 Sep;8(9):2526-36. doi: 10.1158/1535-7163.MCT-09-0300. Epub 2009 Sep 15.

17.

Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.

Ambrosini G, Khanin R, Carvajal RD, Schwartz GK.

Mol Cancer Ther. 2014 Aug;13(8):2073-80. doi: 10.1158/1535-7163.MCT-14-0095. Epub 2014 Jun 4.

18.

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.

Leijen S, Soetekouw PM, Jeffry Evans TR, Nicolson M, Schellens JH, Learoyd M, Grinsted L, Zazulina V, Pwint T, Middleton M.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1619-28. doi: 10.1007/s00280-011-1732-7. Epub 2011 Sep 28.

19.

Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.

van Dijk EH, van Herpen CM, Marinkovic M, Haanen JB, Amundson D, Luyten GP, Jager MJ, Kapiteijn EH, Keunen JE, Adamus G, Boon CJ.

Ophthalmology. 2015 Sep;122(9):1907-16. doi: 10.1016/j.ophtha.2015.05.027. Epub 2015 Jun 26.

PMID:
26123090
20.

Controversies in the management of advanced melanoma: "gray" areas amid the "black and blue".

Jarkowski A 3rd, Norris L, Trinh VA.

Ann Pharmacother. 2014 Nov;48(11):1456-68. doi: 10.1177/1060028014544165. Epub 2014 Jul 23. Review.

PMID:
25056920

Supplemental Content

Support Center